Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
4(33%)
Results Posted
100%(4 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_1
1
8%
Ph phase_2
10
83%

Phase Distribution

1

Early Stage

10

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
10(90.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(4)
Completed(4)
Terminated(3)
Other(1)

Detailed Status

Completed4
Recruiting4
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (9.1%)
Phase 210 (90.9%)

Trials by Status

unknown18%
withdrawn18%
terminated217%
completed433%
recruiting433%

Recent Activity

4 active trials
Showing 5 of 12
recruitingphase_2

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

NCT02828592
recruitingphase_2

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT05736419
recruitingphase_2

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

NCT02143830
recruitingphase_2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
completedphase_1

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

NCT02916979
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02828592Phase 2

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Recruiting
NCT05736419Phase 2

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Recruiting
NCT02143830Phase 2

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Recruiting
NCT06412497Phase 2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting
NCT02916979Phase 1

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

Completed
NCT06087003

Pediatric Induction Therapy in Kidney Transplantation

Completed
NCT05293509Phase 2

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Withdrawn
NCT05214066Phase 2

Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

Unknown
NCT02404025Phase 2

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Completed
NCT01745913Phase 2

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

Terminated
NCT00593554Phase 2

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Terminated
NCT00038857Phase 2

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12